Market capitalization | $9.99b |
Enterprise Value | $10.50b |
P/E (TTM) P/E ratio | 143.47 |
EV/FCF (TTM) EV/FCF | 25.39 |
EV/Sales (TTM) EV/Sales | 5.41 |
P/S ratio (TTM) P/S ratio | 5.15 |
P/B ratio (TTM) P/B ratio | 2.94 |
Revenue growth (TTM) Revenue growth | -1.90% |
Revenue (TTM) Revenue | $1.94b |
As a Free StocksGuide user, you can view scores for all 6,901 stocks worldwide.
21 Analysts have issued a QIAGEN NV forecast:
21 Analysts have issued a QIAGEN NV forecast:
Jun '24 |
+/-
%
|
||
Revenue | 1,940 1,940 |
2%
2%
|
|
Gross Profit | 1,212 1,212 |
3%
3%
|
|
EBITDA | 660 660 |
0%
0%
|
EBIT (Operating Income) EBIT | 450 450 |
1%
1%
|
Net Profit | 73 73 |
78%
78%
|
In millions USD.
If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.
QIAGEN NV is a holding company, which engages in the provision of sample and assay technology to transform biological samples into valuable molecular insights. It offers bioinformatics, molecular diagnostics, next-gen sequencing, and genomic services. The company was founded by Detlev H. Riesner and Metin Colpan on April 29, 1996 and is headquartered in Venlo, the Netherlands.
Head office | Netherlands |
CEO | Thierry Bernard |
Employees | 5,967 |
Founded | 1996 |
Website | www.qiagen.com |
StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.